EPIDEMIOLOGIC REPORT * ETUDE EPIDEMIOLOGIQUE
Use of oral poliovirus vaccine for unlicensed indications
Utilisation du vaccin poliomyelitique buccal pour des indications non autorisees
of live oral polio vaccine (OPV) other live vaccine for the treatment of warts or recurrent herpes simplex infections is totally inappropriate. There is no theoretical justification for such therapy, and the only controlled trial showed no benefit in treating recurrent herpes with OPV.' There is a potential for serious side effects, particularly if recipients or their contacts have unrecognized immuno-
est tout a fait inappropriee d'utiliser le vaccin antipoliomyelitique vivant par voie buccale (VPB) ou tout autre vaccin a virus vivant pour le traitement des verrues ou des infections herpetiques recidivantes. Rien ne justifie une telle therapie sur le plan theorique; le seul essai comparatif effectue n'a revele aucun avantage a traiter ainsi l'herpes recidivant.' Cette utilisation presente un risque de reactions graves, surtout s'il existe une immunodeficience non reconnue chez le sujet vaccine ou chez les personnes qui entrent en contact avec lui.
n he
use or any
deficiency.
II
Reference
Reference
1. Morel P, Vallee G, Civatte J et al: [Ineffectiveness of poliomyelitis vaccine in the treatment of recurrent herpes. A double-blind comparative study with placebo (C)]. Nouv Presse Med 1980; 9: 1099-1100
1. Morel P, Vallee G, Civatte J et al: Inefficacite du vaccin antipoliomyelitique dans le traitement de l'herps recuffent. Etude comparative en double insu avec un placebo [C]. Nouv Presse Med 1980; 9: 1099-1 100
Based on material previously reported in Canada Diseases Weekly Report (a publication of the Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control (LCDC), Department ofNational Health and Welfare, Tunney's Pasture, Ottawa, Ont.) by the National Advisory Committee on Immunization /La declaration estfonde6e sur le materiel pr'ce5demment signale dans le Rapport hebdomadaire des maladies au Canada (une publication du Bureau de l'epidegmiologie des maladies transmissibles, Laboratoire de lutte contre la maladie (LLCM), ministere de la Sante national et du Bien-tre social, Parc Tunney, Ottawa, Ont.) par le Comite consultatif national de l'immunisation Drs./Les D's Susan E. Tamblyn (chairman/presidente), medical officer ofhealth, Perth District Health Unit, Stratford, Ont.; Jacqueline A.K Carlson, physician manager, Disease Control and Epidemiology Service, Ontario Ministry of Health, Toronto, Ont.; John Conly, head, Division ofInfectious Diseases, Royal University Hospital, Saskatoon, Sask.; Gilles Delage, Service de microbiologie et d'immunologie, Hopital Sainte-Justine, Montreal (Que'.); Pierre Dery, chef du Service des maladies infectieuses, Deipartement de pediatrie, Centre hospitalier de l'Universite6 Laval, Sainte-Foy (Que.); John Furesz, director, Bureau of Biologics, Department ofNational Health and Welfare, Ottawa, Ont.; Ronald Gold, chief, Division ofInfectious Diseases, Hospitalfor Sick Children, Toronto, Ont.; Scott A. Halperin, assistant professor ofpediatrics and microbiology, Dalhousie University, Halifax, NS; Gregory Hammond, director, Cadham Provincial Laboratory, Winnipeg, Man.; David W. Scheifele, head, Division ofInfectious Diseases, British Columbia's Children's Hospital, Vancouver, BC; John Spika, director, Bureau of Communicable Disease Epidemiology, LCDC, Department ofNational Health and Welfare, Ottawa, Ont.; David Lorne Tyrrell, chairman, Department ofMedical Microbiology and Infectious Diseases, University ofAlberta, Edmonton, Alta.; and John Waters, director, Communicable Disease Control and Epidemiology, Alberta Community and Occupational Health, Edmonton, Alta. (1991; 17: 75). Publication in CMAJ is with permission of the committee and the bureau / La publication dans le JAMC a ete permise parnle Comit4 et le Bureau. Reprint requests to: Dr. George Wells, Chief, Disease Surveillance Division, Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Tunney's Pasture, Ottawa, ON KIA OL2 / Demandes de reimpression a: Le Dr George Wells, Chef, Division de la surveillance des maladies, Bureau de l'epidfmiologie des maladies transmissibles, Laboratoire de lutte contre la maladie, Parc Tunney, Ottawa, ON KIA OL2
SEPTEMBER 15, 1991
CAN MED ASSOC J 1991; 145 (6)
661
Use of oral poliovirus vaccine for unlicensed indications
Utilisation du vaccin poliomyelitique buccal pour des indications non autorisees
of live oral polio vaccine (OPV) other live vaccine for the treatment of warts or recurrent herpes simplex infections is totally inappropriate. There is no theoretical justification for such therapy, and the only controlled trial showed no benefit in treating recurrent herpes with OPV.' There is a potential for serious side effects, particularly if recipients or their contacts have unrecognized immuno-
est tout a fait inappropriee d'utiliser le vaccin antipoliomyelitique vivant par voie buccale (VPB) ou tout autre vaccin a virus vivant pour le traitement des verrues ou des infections herpetiques recidivantes. Rien ne justifie une telle therapie sur le plan theorique; le seul essai comparatif effectue n'a revele aucun avantage a traiter ainsi l'herpes recidivant.' Cette utilisation presente un risque de reactions graves, surtout s'il existe une immunodeficience non reconnue chez le sujet vaccine ou chez les personnes qui entrent en contact avec lui.
n he
use or any
deficiency.
II
Reference
Reference
1. Morel P, Vallee G, Civatte J et al: [Ineffectiveness of poliomyelitis vaccine in the treatment of recurrent herpes. A double-blind comparative study with placebo (C)]. Nouv Presse Med 1980; 9: 1099-1100
1. Morel P, Vallee G, Civatte J et al: Inefficacite du vaccin antipoliomyelitique dans le traitement de l'herps recuffent. Etude comparative en double insu avec un placebo [C]. Nouv Presse Med 1980; 9: 1099-1 100
Based on material previously reported in Canada Diseases Weekly Report (a publication of the Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control (LCDC), Department ofNational Health and Welfare, Tunney's Pasture, Ottawa, Ont.) by the National Advisory Committee on Immunization /La declaration estfonde6e sur le materiel pr'ce5demment signale dans le Rapport hebdomadaire des maladies au Canada (une publication du Bureau de l'epidegmiologie des maladies transmissibles, Laboratoire de lutte contre la maladie (LLCM), ministere de la Sante national et du Bien-tre social, Parc Tunney, Ottawa, Ont.) par le Comite consultatif national de l'immunisation Drs./Les D's Susan E. Tamblyn (chairman/presidente), medical officer ofhealth, Perth District Health Unit, Stratford, Ont.; Jacqueline A.K Carlson, physician manager, Disease Control and Epidemiology Service, Ontario Ministry of Health, Toronto, Ont.; John Conly, head, Division ofInfectious Diseases, Royal University Hospital, Saskatoon, Sask.; Gilles Delage, Service de microbiologie et d'immunologie, Hopital Sainte-Justine, Montreal (Que'.); Pierre Dery, chef du Service des maladies infectieuses, Deipartement de pediatrie, Centre hospitalier de l'Universite6 Laval, Sainte-Foy (Que.); John Furesz, director, Bureau of Biologics, Department ofNational Health and Welfare, Ottawa, Ont.; Ronald Gold, chief, Division ofInfectious Diseases, Hospitalfor Sick Children, Toronto, Ont.; Scott A. Halperin, assistant professor ofpediatrics and microbiology, Dalhousie University, Halifax, NS; Gregory Hammond, director, Cadham Provincial Laboratory, Winnipeg, Man.; David W. Scheifele, head, Division ofInfectious Diseases, British Columbia's Children's Hospital, Vancouver, BC; John Spika, director, Bureau of Communicable Disease Epidemiology, LCDC, Department ofNational Health and Welfare, Ottawa, Ont.; David Lorne Tyrrell, chairman, Department ofMedical Microbiology and Infectious Diseases, University ofAlberta, Edmonton, Alta.; and John Waters, director, Communicable Disease Control and Epidemiology, Alberta Community and Occupational Health, Edmonton, Alta. (1991; 17: 75). Publication in CMAJ is with permission of the committee and the bureau / La publication dans le JAMC a ete permise parnle Comit4 et le Bureau. Reprint requests to: Dr. George Wells, Chief, Disease Surveillance Division, Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Tunney's Pasture, Ottawa, ON KIA OL2 / Demandes de reimpression a: Le Dr George Wells, Chef, Division de la surveillance des maladies, Bureau de l'epidfmiologie des maladies transmissibles, Laboratoire de lutte contre la maladie, Parc Tunney, Ottawa, ON KIA OL2
SEPTEMBER 15, 1991
CAN MED ASSOC J 1991; 145 (6)
661
